T lymphocytes derived from human cord blood provide effective antitumor immunotherapy against a human tumor

BMC Cancer

Volumn 11, Issue , 2011, Pages

  Lee, Yong Soo ^a   Kim, Tae Sik ^a   Kim, Dong Ku ^b  

^a CHA University   (South Korea)

^b Konkuk University   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

ADOPTIVE TRANSFER; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER IMMUNOTHERAPY; CANCER REGRESSION; CANCER SIZE; CANCER TISSUE; CD3+ T LYMPHOCYTE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CONTROLLED STUDY; CYTOTOXICITY TEST; ENZYME LINKED IMMUNOSPOT ASSAY; FLOW CYTOMETRY; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; IN VIVO STUDY; LUNG CANCER; LYMPHOCYTIC INFILTRATION; MONONUCLEAR CELL; MOUSE; NONHUMAN; OUTCOME ASSESSMENT; SOLID TUMOR; T LYMPHOCYTE; UMBILICAL CORD BLOOD; UTERINE CERVIX CANCER; WART VIRUS; ADOPTIVE IMMUNOTHERAPY; ANIMAL; CELL SEPARATION; CYTOLOGY; CYTOTOXICITY; DRUG SCREENING; FEMALE; FETUS BLOOD; GRAFT VERSUS LEUKEMIA EFFECT; IMMUNOLOGY; INTRALESIONAL DRUG ADMINISTRATION; LUNG TUMOR; METHODOLOGY; MOUSE MUTANT; NEWBORN; NONOBESE DIABETIC MOUSE; T LYMPHOCYTE SUBPOPULATION; TRANSPLANTATION; TUMOR ASSOCIATED LEUKOCYTE; TUMOR CELL LINE; UTERINE CERVIX TUMOR;

CD3 ANTIGEN; T LYMPHOCYTE RECEPTOR; TUMOR ANTIGEN;

ANIMALS; ANTIGENS, CD3; ANTIGENS, NEOPLASM; CELL LINE, TUMOR; CELL SEPARATION; CYTOTOXICITY, IMMUNOLOGIC; FEMALE; FETAL BLOOD; GRAFT VS TUMOR EFFECT; HUMANS; IMMUNOTHERAPY, ADOPTIVE; INFANT, NEWBORN; INJECTIONS, INTRALESIONAL; LUNG NEOPLASMS; LYMPHOCYTES, TUMOR-INFILTRATING; MICE; MICE, INBRED NOD; MICE, SCID; T-CELL ANTIGEN RECEPTOR SPECIFICITY; T-LYMPHOCYTE SUBSETS; UTERINE CERVICAL NEOPLASMS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 79957969078     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-11-225     Document Type: Article

References (35)

1. Bradley MB, Satwani P, Baldinger L, Morris E, van de Ven C, Del Toro G, Garvin J, George D, Bhatia M, Roman E, et al. Reduced intensity allogeneic umbilical cord blood transplantation in children and adolescent recipients with malignant and non-malignant diseases. Bone Marrow Transplant 2007, 40(7):621-631. 10.1038/sj.bmt.1705785, 17660841.
2. Kurtzberg J, Laughlin M, Graham ML, Smith C, Olson JF, Halperin EC, Ciocci G, Carrier C, Stevens CE, Rubinstein P. Placental blood as a source of hematopoietic stem cells for transplantation into unrelated recipients. N Engl J Med 1996, 335(3):157-166. 10.1056/NEJM199607183350303, 8657213.
3. Wagner JE, Rosenthal J, Sweetman R, Shu XO, Davies SM, Ramsay NK, McGlave PB, Sender L, Cairo MS. Successful transplantation of HLA-matched and HLA-mismatched umbilical cord blood from unrelated donors: analysis of engraftment and acute graft-versus-host disease. Blood 1996, 88(3):795-802.
4. Amlot PL, Tahami F, Chinn D, Rawlings E. Activation antigen expression on human T cells. I. Analysis by two-colour flow cytometry of umbilical cord blood, adult blood and lymphoid tissue. Clin Exp Immunol 1996, 105(1):176-182. 10.1046/j.1365-2249.1996.d01-722.x, 2200463, 8697627.
5. Beck R, Lam-Po-Tang PR. Comparison of cord blood and adult blood lymphocyte normal ranges: a possible explanation for decreased severity of graft versus host disease after cord blood transplantation. Immunol Cell Biol 1994, 72(5):440-444. 10.1038/icb.1994.65, 7835989.
6. D'Arena G, Musto P, Cascavilla N, Di Giorgio G, Fusilli S, Zendoli F, Carotenuto M. Flow cytometric characterization of human umbilical cord blood lymphocytes: immunophenotypic features. Haematologica 1998, 83(3):197-203.
7. Han P, Hodge G, Story C, Xu X. Phenotypic analysis of functional T-lymphocyte subtypes and natural killer cells in human cord blood: relevance to umbilical cord blood transplantation. Br J Haematol 1995, 89(4):733-740.
8. Garderet L, Dulphy N, Douay C, Chalumeau N, Schaeffer V, Zilber MT, Lim A, Even J, Mooney N, Gelin C, et al. The umbilical cord blood alphabeta T-cell repertoire: characteristics of a polyclonal and naive but completely formed repertoire. Blood 1998, 91(1):340-346.
9. Schelonka RL, Raaphorst FM, Infante D, Kraig E, Teale JM, Infante AJ. T cell receptor repertoire diversity and clonal expansion in human neonates. Pediatr Res 1998, 43(3):396-402. 10.1203/00006450-199803000-00015, 9505280.
10. Anderson LD, Mori S, Mann S, Savary CA, Mullen CA. Pretransplant tumor antigen-specific immunization of allogeneic bone marrow transplant donors enhances graft-versus-tumor activity without exacerbation of graft-versus-host disease. Cancer Res 2000, 60(20):5797-5802.
11. Edinger M, Hoffmann P, Ermann J, Drago K, Fathman CG, Strober S, Negrin RS. CD4+CD25+ regulatory T cells preserve graft-versus-tumor activity while inhibiting graft-versus-host disease after bone marrow transplantation. Nat Med 2003, 9(9):1144-1150. 10.1038/nm915, 12925844.
12. Eibl B, Schwaighofer H, Nachbaur D, Marth C, Gachter A, Knapp R, Bock G, Gassner C, Schiller L, Petersen F, et al. Evidence for a graft-versus-tumor effect in a patient treated with marrow ablative chemotherapy and allogeneic bone marrow transplantation for breast cancer. Blood 1996, 88(4):1501-1508.
13. Ito M, Shizuru JA. Graft-vs.-lymphoma effect in an allogeneic hematopoietic stem cell transplantation model. Biol Blood Marrow Transplant 1999, 5(6):357-368. 10.1016/S1083-8791(99)70012-1, 10595813.
14. Feuerer M, Beckhove P, Bai L, Solomayer EF, Bastert G, Diel IJ, Pedain C, Oberniedermayr M, Schirrmacher V, Umansky V. Therapy of human tumors in NOD/SCID mice with patient-derived reactivated memory T cells from bone marrow. Nat Med 2001, 7(4):452-458. 10.1038/86523, 11283672.
15. Evans EM, Man S, Evans AS, Borysiewicz LK. Infiltration of cervical cancer tissue with human papillomavirus-specific cytotoxic T-lymphocytes. Cancer Res 1997, 57(14):2943-2950.
16. Ressing ME, van Driel WJ, Celis E, Sette A, Brandt MP, Hartman M, Anholts JD, Schreuder GM, ter Harmsel WB, Fleuren GJ, et al. Occasional memory cytotoxic T-cell responses of patients with human papillomavirus type 16-positive cervical lesions against a human leukocyte antigen-A *0201-restricted E7-encoded epitope. Cancer Res 1996, 56(3):582-588.
17. Livingston RB. Combined modality therapy of lung cancer. Clin Cancer Res 1997, 3(12 Pt 2):2638-2647.
18. Pilon-Thomas SA, Verhaegen ME, Mule JJ. Dendritic cell-based therapeutics for breast cancer. Breast Dis 2004, 20:65-71.
19. Srinivasan R, Van Epps DE. Specific active immunotherapy of cancer: potential and perspectives. Rev Recent Clin Trials 2006, 1(3):283-292. 10.2174/157488706778250113, 18473980.
20. Yan L, Hsu K, Beckman RA. Antibody-based therapy for solid tumors. Cancer J 2008, 14(3):178-183. 10.1097/PPO.0b013e318172d71a, 18536557.
21. Hagihara M, Gansuvd B, Ueda Y, Tsuchiya T, Masui A, Tazume K, Inoue H, Kato S, Hotta T. Killing activity of human umbilical cord blood-derived TCRValpha24(+) NKT cells against normal and malignant hematological cells in vitro: a comparative study with NK cells or OKT3 activated T lymphocytes or with adult peripheral blood NKT cells. Cancer Immunol Immunother 2002, 51(1):1-8. 10.1007/s00262-001-0246-2, 11845254.
22. Joshi AD, Clark EM, Wang P, Munger CM, Hegde GV, Sanderson S, Dave HP, Joshi SS. Immunotherapy of human neuroblastoma using umbilical cord blood-derived effector cells. J Neuroimmune Pharmacol 2007, 2(2):202-212. 10.1007/s11481-006-9038-y, 18040845.
23. Lin P, Lu YR, Zhang J, Wei YQ, Wang XJ, Li SF, Wang Q, Xiong ZJ, Ning QZ, Lei S, et al. Antitumor effect of lung cancer vaccine with umbilical blood dendritic cells in reconstituted SCID mice. Cancer Biother Radiopharm 2008, 23(3):321-331. 10.1089/cbr.2008.0463, 18593365.
24. Lovgren TR, Tarantolo SR, Evans C, Kuszynski CA, Joshi SS. Enhanced in vitro and in vivo cytotoxicity of umbilical cord blood cells against human breast cancer following activation with IL-15 and colony stimulating factors. In Vivo 2002, 16(6):541-550.
25. Knutson KL, Disis ML. Tumor antigen-specific T helper cells in cancer immunity and immunotherapy. Cancer Immunol Immunother 2005, 54(8):721-728. 10.1007/s00262-004-0653-2, 16010587.
26. Hiramatsu H, Nishikomori R, Heike T, Ito M, Kobayashi K, Katamura K, Nakahata T. Complete reconstitution of human lymphocytes from cord blood CD34+ cells using the NOD/SCID/gammacnull mice model. Blood 2003, 102(3):873-880. 10.1182/blood-2002-09-2755, 12689924.
27. Yu Y, Hagihara M, Ando K, Gansuvd B, Matsuzawa H, Tsuchiya T, Ueda Y, Inoue H, Hotta T, Kato S. Enhancement of human cord blood CD34+ cell-derived NK cell cytotoxicity by dendritic cells. J Immunol 2001, 166(3):1590-1600.
28. Hogan CJ, Shpall EJ, Keller G. Differential long-term and multilineage engraftment potential from subfractions of human CD34+ cord blood cells transplanted into NOD/SCID mice. Proc Natl Acad Sci USA 2002, 99(1):413-418. 10.1073/pnas.012336799, 117574, 11782553.
29. van der Loo JC, Hanenberg H, Cooper RJ, Luo FY, Lazaridis EN, Williams DA. Nonobese diabetic/severe combined immunodeficiency (NOD/SCID) mouse as a model system to study the engraftment and mobilization of human peripheral blood stem cells. Blood 1998, 92(7):2556-2570.
30. Nakagawa M, Stites DP, Farhat S, Sisler JR, Moss B, Kong F, Moscicki AB, Palefsky JM. Cytotoxic T lymphocyte responses to E6 and E7 proteins of human papillomavirus type 16: relationship to cervical intraepithelial neoplasia. J Infect Dis 1997, 175(4):927-931. 10.1086/513992, 9086151.
31. Nimako M, Fiander AN, Wilkinson GW, Borysiewicz LK, Man S. Human papillomavirus-specific cytotoxic T lymphocytes in patients with cervical intraepithelial neoplasia grade III. Cancer Res 1997, 57(21):4855-4861.
32. Youde SJ, Dunbar PR, Evans EM, Fiander AN, Borysiewicz LK, Cerundolo V, Man S. Use of fluorogenic histocompatibility leukocyte antigen-A*0201/HPV 16 E7 peptide complexes to isolate rare human cytotoxic T-lymphocyte-recognizing endogenous human papillomavirus antigens. Cancer Res 2000, 60(2):365-371.
33. Haddad R, Guardiola P, Izac B, Thibault C, Radich J, Delezoide AL, Baillou C, Lemoine FM, Gluckman JC, Pflumio F, et al. Molecular characterization of early human T/NK and B-lymphoid progenitor cells in umbilical cord blood. Blood 2004, 104(13):3918-3926. 10.1182/blood-2004-05-1845, 15331438.
34. Lucivero G, Dalla Mora L, Bresciano E, Loria MP, Pezone L, Mancino D. Functional characteristics of cord blood T lymphocytes after lectin and anti-CD3 stimulation. Differences in the way T cells express activation molecules and proliferate. Int J Clin Lab Res 1996, 26(4):255-261. 10.1007/BF02602959, 9007617.
35. Nonoyama S, Penix LA, Edwards CP, Lewis DB, Ito S, Aruffo A, Wilson CB, Ochs HD. Diminished expression of CD40 ligand by activated neonatal T cells. J Clin Invest 1995, 95(1):66-75. 10.1172/JCI117677, 295372, 7814647.